Clinical Trials Browser

Phase 2/3 × INDUSTRY × Differentiated Thyroid Cancer × Clear all

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Phase 2/3 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer